|
Question on the Use of Composite Outcomes vs. All-Cause Mortality in Drug Trials
|
|
9
|
313
|
May 21, 2025
|
|
Obtaining a continuous estimate from ordinal data
|
|
14
|
610
|
May 20, 2025
|
|
Challenges in determining meaningful between group differences of surgery vs non-surgical treatment
|
|
12
|
922
|
May 9, 2025
|
|
Why the Non-Reproducibility of Acute Care RCT? The CAP studies
|
|
6
|
300
|
May 8, 2025
|
|
Sample size and duration of follow-up of randomized controlled clinical trials
|
|
11
|
488
|
April 28, 2025
|
|
Alpha spending/information fraction when controlling for baseline covariate
|
|
2
|
675
|
January 29, 2025
|
|
How to handle data requiring truncation to be valid
|
|
2
|
621
|
January 25, 2025
|
|
Responder Analysis: Loser x 4
|
|
22
|
37781
|
January 9, 2025
|
|
Summary table of different Cox PHM models to compare them
|
|
7
|
1086
|
December 23, 2024
|
|
Non Inferiority vs Non significant
|
|
17
|
1775
|
December 19, 2024
|
|
Screening for risk of sudden cardiac death in athletes
|
|
7
|
825
|
December 14, 2024
|
|
Validation of a Simulation-Based Methodology for Power and Sample Size Calculation Using the Wilcoxon Test
|
|
2
|
781
|
December 4, 2024
|
|
Determining the accuracy of wearable monitoring devices
|
|
5
|
990
|
November 13, 2024
|
|
Is it a good idea to use two estimators for multilevel meta-regression?
|
|
0
|
434
|
October 19, 2024
|
|
Learning how to conduct and design meaningful clinical trials
|
|
8
|
1617
|
September 3, 2024
|
|
Non-collapsibility of standardized rate
|
|
14
|
1405
|
August 31, 2024
|
|
Effect sizes for power and evidence for effectiveness
|
|
24
|
2911
|
July 24, 2024
|
|
Power and sample size planning with canonical correlation analysis
|
|
3
|
1425
|
July 23, 2024
|
|
Recovering utilities implicit in adaptive trial designs
|
|
5
|
1197
|
July 18, 2024
|
|
Health economic state-based transition models
|
|
3
|
1229
|
July 3, 2024
|
|
Progression in cancer trials
|
|
26
|
6032
|
June 25, 2024
|
|
Quality literature on the design and logistics of conducting a randomized controlled trial
|
|
4
|
4001
|
June 20, 2024
|
|
Power for a mixed ANOVA (2b x 2w)
|
|
2
|
960
|
June 8, 2024
|
|
Comparisons of Physicians and LLMs with Technical Replicates
|
|
1
|
1051
|
June 6, 2024
|
|
Method comparison study: Multiple experts vs AI
|
|
8
|
2103
|
May 21, 2024
|
|
Definition of Intention-to-Treat Set in Epic generated randomization
|
|
16
|
2852
|
May 4, 2024
|
|
Double Counting in Meta-Analysis
|
|
3
|
1040
|
April 10, 2024
|
|
Sample size calculation for metabolomic profiles in a nested case-control study
|
|
0
|
1055
|
April 8, 2024
|
|
Immortal-time-bias vs. selection bias
|
|
2
|
1882
|
April 7, 2024
|
|
Run-in phase in RCTs
|
|
14
|
10569
|
April 1, 2024
|